S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:NTLA

Intellia Therapeutics - NTLA Stock Forecast, Price & News

$43.23
-1.37 (-3.07%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$42.42
$44.51
50-Day Range
$33.21
$51.46
52-Week Range
$32.44
$104.87
Volume
785,292 shs
Average Volume
1.14 million shs
Market Capitalization
$3.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.16

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
131.7% Upside
$100.16 Price Target
Short Interest
Bearish
8.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.28mentions of Intellia Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$431,934 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.09) to ($5.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

71st out of 1,029 stocks

Diagnostic Substances Industry

3rd out of 15 stocks

NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

Does Intellia Therapeutics Stock Have Good Genes?
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Intellia Therapeutics (NASDAQ:NTLA) Trading 4.2% Higher
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Verve Therapeutics Crushed By Clinical Hold
SVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Earnings Preview For Intellia Therapeutics
10 Best Gene Editing Stocks To Buy
Intellia Therapeutics Inc (38I)
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Company Calendar

Last Earnings
11/04/2021
Today
2/04/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$100.16
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+131.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-267,890,000.00
Net Margins
-859.92%
Pretax Margin
-859.92%

Debt

Sales & Book Value

Annual Sales
$33.05 million
Book Value
$14.15 per share

Miscellaneous

Free Float
75,615,000
Market Cap
$3.40 billion
Optionable
Optionable
Beta
1.90

Key Executives

  • John M. LeonardJohn M. Leonard
    President, Chief Executive Officer & Director
  • Glenn GoddardGlenn Goddard
    Treasurer, Chief Financial & Accounting Officer
  • Laura Sepp-LorenzinoLaura Sepp-Lorenzino
    Chief Scientific Officer & Executive VP
  • David LebwohlDavid Lebwohl
    Chief Medical Officer & Executive Vice President
  • Eliana Clark
    Chief Technology Officer & Executive VP













NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2023?

18 Wall Street research analysts have issued 12-month price targets for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $39.00 to $180.00. On average, they predict the company's share price to reach $100.16 in the next year. This suggests a possible upside of 131.7% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2023?

Intellia Therapeutics' stock was trading at $34.89 at the beginning of the year. Since then, NTLA shares have increased by 23.9% and is now trading at $43.23.
View the best growth stocks for 2023 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.12. The business earned $7.20 million during the quarter, compared to analyst estimates of $8.66 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative trailing twelve-month return on equity of 47.79%. The business's revenue was down 67.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) earnings per share.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.97%), Sumitomo Mitsui Trust Holdings Inc. (3.78%), Capital Advisors Inc. OK (0.22%), Gratus Capital LLC (0.09%), New York State Common Retirement Fund (0.08%) and State of New Jersey Common Pension Fund D (0.06%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $43.23.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.40 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 485 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 2/4/2023 by MarketBeat.com Staff